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Abstract
Insights into long-term mortality, especially into the cause of death after initial recovery from an episode of community-acquired pneu-
monia (CAP), may help in determining optimal preventive measures in such patients. Prospective observational cohort studies were
conducted to compare cause-specific long-term mortality rates for 356 patients who had recovered from CAP with those of the gen-
eral Dutch population (16.3 million) between 2003 and 2007. The Dutch Municipal Public Records Database and death certificates were
used to determine cause-specific mortality rates up to 7 years after discharge. In patients who had recovered from CAP, cumulative
1-year, 5-year and 7-year mortality rates were 17%, 43% and 53%, respectively, as compared with 4%, 19% and 24% for an age-matched
and sex-matched population reference cohort. Overall, patients who had recovered from CAP had significantly higher long-term mortal-
ity than matched population controls (rate ratio (RR) 3.6; p <0.001). In the years after an episode of CAP, malignancy (27%), chronic
obstructive pulmonary disease (COPD) (19%) and cardiovascular disease (16%) were the most frequent causes of death. Only 6% died
of pneumonia, as compared with 3.2% in the general population. After initial recovery from an episode of CAP, long-term mortality
rates are more than three times as high as in the general population. The causes of long-term mortality were mostly comorbidity-
related, and significantly different from those in the general population. After an episode of CAP, optimization of treatment of comor-
bidities, such as treatment for COPD, might improve long-term survival rates.
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Introduction
Despite advances in healthcare, current antibiotic therapy,
and vaccination strategies against pneumococci and influenza,
community-acquired pneumonia (CAP) is still the major
cause of mortality from infectious diseases in developed
countries. Worldwide, pneumonia accounts for 4.2 million
deaths annually, and the risk factors associated with mortality
from acute episodes of CAP have been well studied [1–3].
Additionally, several studies have suggested that the long-
term implications of CAP reach far beyond the diagnosis;
high numbers of re-admissions and high mortality rates in
the first years after hospitalization have been described
[4–12]. The long-term contribution to mortality of a hospi-
talization for CAP was suggested to be even higher than the
contribution of hospitalizations for other reasons than CAP
in a matched study population [5,9].
Increasing age and comorbid illnesses have been identified
as risk factors for increased mortality after an episode of
CAP [4,5,9,13]. Although these parameters provide an
impression of causes of death in the years following an
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episode of pneumonia, data on cause-specific long-term mor-
tality after initial recovery from CAP are limited. To the best
of our knowledge, the actual causes of death and the risk for
mortality after initial recovery in the years after an episode
of CAP as compared with the general population have not
been described in detail before. Better insights into cause-
specific mortality in the years after hospitalization for an epi-
sode of CAP can help in the determination of optimal pre-
ventive measures, such as vaccination strategies or treatment
of chronic obstructive pulmonary disease (COPD), in
patients who have recovered from CAP.
Therefore, we studied mortality rates and causes of death
up to 7 years after hospitalization in patients who had initially
recovered from an episode of CAP treated in a non-inten-
sive-care setting, and compared them with age-matched and
sex-matched mortality rates in the general Dutch population.
Materials and Methods
Study population and setting
A prospective cohort of CAP patients was derived from two
randomized, double-blind, placebo-controlled, multicentre
trials on antibiotic treatment strategies for CAP among
patients hospitalized in general medical and pulmonary wards
[14,15]. One trial was conducted in patients with moderate
to severe CAP (pneumonia severity index (PSI) >90), and
evaluated the cost-effectiveness of an early switch from par-
enteral to oral therapy [14]. The second trial included
patients with mild to moderate/severe CAP (PSI £90), and
compared two durations of treatment for CAP [15]. The tri-
als were conducted during a 3-year period from July 2000 to
July 2003 in three university medical centres and eight of
their affiliated teaching hospitals in The Netherlands. Inclu-
sion and exclusion criteria have been reported in detail pre-
viously [14,15]. In short, all adult patients (aged 18 years or
above) admitted to the hospital because of CAP were eligible
for inclusion in either one of the trials. CAP was defined as
at least two symptoms of acute lower respiratory tract infec-
tion with onset before admission, and a new or progressive
pulmonary infiltrate on a chest radiograph [16,17]. The study
protocols were reviewed and approved by the ethics com-
mittees of all participating hospitals. Written and oral
informed consent was obtained from all patients included.
Cause-specific long-term mortality rates
The vital status of the individual patients discharged after an
episode of CAP was determined from the Dutch Municipal
Public Records Database as of 1 June 2008. This national
database contains the official testimony of a person’s death
issued by the patient’s physician, including the date of death.
Death certificates retrieved from Statistics Netherlands were
used to determine the cause of death for those who died in
the follow-up period [18]. Statistics Netherlands approved
the use of the death certificate register for this study.
Causes of death listed on the death certificates were coded
in International Classification of Diseases 10th revision (ICD-
10) codes. In a subset of 25% of patients who had died, case
studies for causes of death were conducted to account for
possible bias resulting from coding. Case studies of medical
records were performed by two physicians independently.
When there was disagreement among the physicians, the
case was discussed to reach a consensus.
Dutch general population cohort
An age-matched and sex-matched general population cohort
was retrieved from the life-expectancy data of the general
Dutch population (16.3 million) from Statistics Netherlands,
which are available online [18]. Statistics Netherlands holds a
national database containing demographic data, healthcare
variables and life-expectancy data, based on official testimo-
nies of death issued by physicians. Average mortality rates
and ICD-10-coded causes of death were calculated over a
5-year period from 2003 to 2007.
Analytical approach and statistical analysis
We examined annual and cumulative mortality rates up to
7 years after discharge, and compared the mortality rates
with those of the general population, using chi-squared tests
and rate ratios (RRs). Comparative survival curves and
curves stratified for age were constructed using Kaplan–
Meier methodology. Cox regression analysis was used to
study predictors for mortality in discharged patients. Any
variable that was univariately associated with all-cause
mortality (p £0.20) was entered into a forward stepwise
Cox proportional hazards model.
To assess agreement between the ICD-10-coded causes
of death and the causes of death as determined by our physi-
cians, kappa statistics were calculated. All causes of death in
CAP patients, reported in ICD-10 codes, were reviewed and
categorized according to organ system for analysis. Stratified
analysis of causes of death for year of follow-up was con-
ducted. Causes of death in patients who had recovered from
pneumonia were compared with causes of death in the
matched general Dutch population cohort by chi-squared
tests and crude ORs. All reported p-values are two-tailed,
and p-values of <0.05 were considered to represent statisti-
cal significance. Statistical analysis was performed with the
statistical software package SPSS 15.0 for Windows (SPSS,
Chicago, IL, USA).
764 Clinical Microbiology and Infection, Volume 17 Number 5, May 2011 CMI
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 763–768
Results
Characteristics of the study population
In total, 356 cases discharged because of pneumonia were
included and matched with a general population cohort. Ini-
tially, 390 patients discharged from the hospital after an epi-
sode of CAP were eligible for inclusion. For 356 (91.3%) of
these, we were able to retrieve the survival status, and they
were subsequently included for analysis. No significant differ-
ences in age, pneumonia severity or comorbidities were
found between patients without retrieved documentation on
survival status and patients included.
The mean age (± standard deviation) of the CAP patients
was 66.0 ± 16.1 years, and 131 (36.8%) were male; both of
these were comparable in the matched population cohort. As
expected, patients who survived CAP were more burdened by
COPD than the general population, whereas overall rates of
comorbidities were comparable (63.5% vs. 64.0%) (Table 1).
Long-term mortality rates after hospitalization for CAP
Of the 356 patients discharged from hospital after an epi-
sode of CAP, eight (2%) died in the first month after dis-
charge. The overall mean survival after hospital discharge
was 1565 days, 2299 days (6.5 years) for survivors and
932 days (2.6 years) for non-survivors.
Cumulative 1-year, 5-year and 7-year mortality rates were
17%, 43% and 53%, respectively, as compared with 4.2%,
19% and 24% in the general population. Overall, patients
who had recovered from an episode of CAP had a signifi-
cantly higher long-term mortality rate (52.5%) than general
population controls (23.5%) (RR 3.6; p <0.001). In particular,
annual mortality rates within the first 3 years of follow-up
were significantly higher in those who had recovered from
pneumonia than in the general population (p £0.004)
(Table 2). The data also indicate that long-term mortality
rates are higher in the cohort of severe CAP than in the
cohort of moderate to severe CAP (30.9% vs. 65.9%;
p <0.001).
TABLE 1. Characteristics of the study cohort of 356 patients discharged from the hospital after an episode of community-
acquired pneumonia (CAP) and of an age-matched and sex-matched Dutch population cohort
Variable
Mild to moderate/severe
CAP (PSI £90) (n = 136)
Moderate to severe
CAP (PSI >90) (n = 220)
All CAP patients
(n = 356)
Population
cohort (%)
Age (mean years) ± SD 56.1 ± 17.6 71.9 ± 10.8 66 ± 16.1 67 ± 2.3
Male 36.0 (49) 37.3 (82) 36.8 (131) 36.0
Nursing home patient 2.9 (4) 3.6 (8) 3.4 (12) 0.8
Comorbidity 56.6 (77) 67.7 (149) 63.5 (226) 64.0
Chronic heart failure 13.9 (19) 15.9 (35) 15.2 (54) 9.9
Malignancy 3.6 (5) 25.9 (57) 17.4 (62) 22.3
Chronic obstructive pulmonary disease 25.7 (35) 33.1 (73) 30.3 (108) 19.0
Liver disease 0 (0) 0.9 (2) 0.56 (2) 1.2
Renal disease 0.7 (1) 9.5 (21) 6.2 (22) 5.3
Cerebrovascular disease 2.2 (3) 9.1 (20) 6.5 (23) 10.5
PSI, pneumonia severity index; SD, standard deviation.
Data are % (no. of patients) unless otherwise indicated.
TABLE 2. Annual and cumulative mortality rates of community-acquired pneumonia (CAP) patients as compared with
age-matched and sex-matched Dutch population controls
Interval
(year)
Mild to moderate/
severe CAP (PSI £90),
n = 136
Moderate to severe CAP
(PSI >90), n = 220
All CAP patients,
n = 356 Population controlsa
Rate
ratiob p
Annual
rate
Cumulative
rate
Annual
rate
Cumulative
rate
Annual
rate
Cumulative
rate
Annual
rate
Cumulative
rate
1 5.9 (8) 5.9 (8) 23.6 (52) 23.6 (52) 16.9 (60) 16.9 (60) 4.2 4.2 4.02 <0.001
2 5.1 (7) 11.0 (15) 11.8 (26) 35.5 (78) 9.3 (33) 26.1 (93) 4.0 8.2 2.33 <0.001
3 5.1 (7) 16.2 (22) 9.1 (20) 44.5 (98) 7.6 (27) 33.7 (120) 3.8 12.1 2.00 <0.001
4 3.7 (5) 19.9 (27) 5.9 (13) 50.5 (111) 5.1 (18) 38.8 (138) 3.5 15.5 1.46 0.12
5 2.2 (3) 22.1 (30) 5.9 (13) 56.4 (124) 4.5 (16) 43.3 (154) 3.1 18.6 1.45 0.13
6 3.7 (5) 25.8 (35) 6.8 (15) 63.2 (139) 5.6 (20) 48.9 (174) 2.6 21.3 2.15 < 0.001
7 5.1 (7) 30.9 (42) 2.8 (6) 65.9 (145) 3.6 (13) 52.5 (187) 2.5 23.8 1.44 0.77
Cumulative rate, cumulative mortality rate; PSI, pneumonia severity index.
Data are % (no. of patients).
aFor the population control cohort, mean values of mortality rates over a 5-year period (2003–2007) are given.
bRate ratio reflects the difference in annual mortality rates between all CAP patients and population controls.
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Predictors of long-term mortality after hospitalization for
CAP
Age, PSI score, nursing home residency and comorbid illnesses
such as malignancy, COPD and congestive heart failure were
associated with a higher risk for mortality in univariate analyses.
In a final multivariable Cox regression model, comorbidity (haz-
ard ratio (HR) 1.72; 95% CI 1.12–2.65), neoplasm (HR 2.07;
95% CI 1.37–3.13), age >65 years (HR 1.96; 95% CI 1.29–
3.00), moderate to severe pneumonia (PSI >90) (HR 2.13;
95% CI 1.40–3.24) and nursing home residence (HR 2.04;
95% CI 1.12–3.74) were independently associated with
increased mortality during long-term follow-up (appendix 1).
Causes of death during long-term follow-up after hospital-
ization for CAP
Causes of death could be retrieved in 174 of the 187 (93%)
patients who died during long-term follow-up after an epi-
sode of CAP. In 13 patients, the cause of death could not be
retrieved, owing to unsuccessful linkage of patients’ demo-
graphic data with the death certificates, mainly because of
change of residence. Good agreement was observed
between ICD-10-coded causes of death and those deter-
mined by physicians (mean kappa 0.82).
Most CAP patients died because of malignancy (26.7%;
n = 50), respiratory diseases (27.3%; n = 51) (19.3% (n = 36)
from COPD), and vascular diseases (16.0%; n = 30) (Table 3).
Eleven (5.9%) patients died from recurrent pneumonia.
Fig. 1 shows the causes of death per year of follow-up. Malig-
nancy as the cause of death was most frequent in the first year
after discharge. Other comorbidities did not show an excess
mortality in the first years after discharge from the hospital.
Causes of death as compared with the general Dutch population
We compared the main causes of death in CAP patients with
causes of death in the general population cohort. Causes of
death in CAP patients differed significantly from those in the
general population (p <0.001). As shown in Table 3, patients
who survived an episode of CAP had an approximately four-
fold increased risk of having COPD listed as their cause of
death as compared with the general population (19.3% vs.
4.4%; RR 4.38; 95% CI 3.26–5.87). In contrast, general popu-
lation controls had a higher risk of death from cardiovascular
diseases than the CAP population (30.2% vs. 16.0%; RR 0.53;
95% CI 0.38–0.74). Also, 5.9% of patients who had had a
previous episode of CAP died of recurrent pneumonia, as
compared with a 3.2% risk of death from pneumonia in the
general population (RR 1.84; 95% CI 1.04–3.26). The fre-
quency of malignancy as the cause of death was slightly
higher in the control population than in the pneumonia
cohort (33.8% vs. 26.7%; RR 0.79; 95% CI 0.62–1.00).
Discussion
On the basis of these results, we can draw three main con-
clusions.
First, mortality during long-term follow-up of patients with
CAP is high, considerably higher than in the general popula-
tion: up to 53% after 7 years as compared with 24% in an
age-matched and sex-matched general population cohort.
The excess mortality in CAP patients is most exaggerated in
the first 3 years of follow-up.
Previous studies reported 1-year mortality rates after
CAP of 11–22% and 5-year mortality rates of 38–53% [6,10–
12,19]. The wide range in these long-term mortality rates is
probably best explained by differences in the studied popula-
tions [5,6,12,19]. Current data indicate that patients who
TABLE 3. Causes of death in the community-acquired
pneumonia (CAP) patients as compared with population
controls
CAP patients
(n = 187)
Population
controls RR (95% CI) pa
Pneumonia 5.9 (11) 3.2 1.84 (1.04–3.26) <0.001
COPD 19.3 (36) 4.4 4.38 (3.26–5.87)
Vascular 16.0 (30) 30.2 0.53 (0.38–0.74)
Malignancy 26.7 (50) 33.8 0.79 (0.62–1.00)
Other causes
of deathb
32.1 (60) 28.3 1.13 (0.92–1.40)
COPD, chronic obstructive pulmonary disease; RR, relative risk.
Data are % (no. of patients) unless otherwise indicated.
ap value for v2 tests for comparison between proportions of causes of death in
CAP patient and proportions of causes of death in age and sex matched popula-
tion controls.
bIncludes unknown causes of death in CAP patients (n = 13).
FIG. 1. Causes of death in the years following hospitalization for an
episode of community-acquired pneumonia (CAP). COPD, chronic
obstructive pulmonary disease.
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survive an episode of pneumonia have a much higher risk of
dying in subsequent years than the general population. One
explanation is that pneumonia represents a marker of poor
general health status; another is that a less aggressive
approach in the treatment and risk management of these
‘frail’ CAP patients may be chosen. Noticeably, most risk fac-
tors for mortality during long-term follow-up of CAP, identi-
fied here and by others, are not associated with acute illness
but are related to comorbidity, and seem to be general mea-
sures of frailty [4–7,9,10,12,19].
Second, we showed that CAP patients are more likely to
die from comorbid illnesses such as malignancy, cardiovascu-
lar diseases or COPD than from recurrent pneumonia. One
other study reported the causes of 51 deaths after an epi-
sode of pneumonia, and identified cardiovascular diseases
and malignancies as also being important causes of death [7].
These results emphasize the importance of optimal manage-
ment of comorbidities in CAP patients. Although we are
aware that the natural courses of some of these diseases
may not be altered, early recognition and intervention for
comorbidities maximizes the possibility of favourable long-
term prognosis. The incidence of probably inevitable deaths
from malignancies was highest in the first year after CAP,
whereas deaths from more treatable causes, such as cardio-
vascular disease and COPD, occurred at a more constant
level during follow-up. Therefore, screening of pneumonia
patients at discharge or shortly afterwards for vascular dis-
eases or COPD could be one of the preventive approaches
to take.
Third, we showed that there are differences in the causes
of death between patients who had recovered from CAP
and the general population. It is of interest that 5.9% of CAP
patients died because of a recurrent episode of pneumonia,
as compared with 3.2% deaths from pneumonia in the gen-
eral population. Individuals who recovered from pneumonia
had a four-fold increased risk of dying because of COPD as
compared with the general population. This could be a result
of confounding, as the prevalence of COPD is higher in the
CAP cohort than in population controls [20]. Otherwise, it
can be reasoned that an episode of pneumonia negatively
affects the prognosis of COPD and that more intensive
treatment of COPD is warranted at the moment of recovery
from CAP [21,22]. Remarkably, and in contrast to the find-
ings of Koivola et al. [6], CAP patients had a two-fold lower
risk of dying because of cardiovascular diseases than the
general population. One explanation could be that the CAP
patients in the present study have more complex comorbidi-
ties, and are therefore more likely to die from these than
from vascular diseases. On the other hand, it can be rea-
soned that the rate of cardiovascular death is underesti-
mated or masked by respiratory illnesses, and that more
screening and better diagnostics for vascular diseases are
needed in our population.
Our study has several limitations. We used death certifi-
cates to identify causes of death. It has been reported that
death certificates are not always in concordance with
autopsy findings. However, the suggested lack of concor-
dance may be overestimated, as autopsies are mostly con-
ducted when the cause of death is not clear [23]. Moreover,
our subset analysis showed a good agreement between ICD-
10-coded causes of death and causes of death determined by
case studies conducted by physicians. In addition, the cohort
of CAP patients was not population-based but retrieved
from two prospective randomized controlled trials, which
may limit the generalizability. Patients were followed for
30 days. Unfortunately, data on smoking, vaccination and
functional status, lung function and re-admissions after
day 30 were not available to us. Also, data from general
population controls were retrieved from nationwide databas-
es, and we were not able to prospectively collect individual
information on the medical histories of the control patients.
Theoretically, CAP patients could have formed part of the
population cohort as well, implying that the results for differ-
ential mortality rates in CAP patients and controls are rather
underestimated. Furthermore, our results reflect long-term
mortality rates of immunocompetent patients who are
admitted to general wards in a country with a high influenza
vaccination rate [24]. Therefore, the results cannot be gen-
eralized to other populations with CAP, such as intensive-
care unit patients, outpatients, immunocompromised
patients, or communities with a low rate of vaccination for
influenza.
In conclusion, long-term mortality rates after initial reco-
very from CAP in patients admitted to general wards are high;
up to 53% after 7 years, and considerably higher than in the
general population. Causes of death in the years following an
episode of CAP are mostly comorbidity-related, and not
attributable to recurrent pneumonia. Causes of death in CAP
patients were significantly different from those in population
controls. Therefore, awareness among physicians of excess
long-term mortality in patients who have recovered from an
episode of CAP seems warranted. After an episode of CAP,
optimization of the treatment of comorbidities, such as treat-
ment for COPD, might improve long-term survival rates.
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Appendix 1
Multivariate Cox proportional hazard analysis for parameters
associated with death after hospitalization for an episode of
CAP
Hazard ratio
(95% CI) p
Comorbiditya 1.72 (1.12–2.65) 0.01
Malignancy 2.07 (1.37–3.13) 0.002
Age >65 years 1.96 (1.29–3.00) 0.02
PSI score > 90 2.13 (1.40–3.24) <0.001
Nursing home residency 2.04 (1.12–3.74) 0.001
Parameters investigated in univariate analysis were: patient characteristics (age,
gender, comorbid illnesses); treatment in academic hospital; pneumonia severity
index (PSI); symptoms and signs (dyspnoea, temperature, respiratory rate, oxy-
gen saturation, oxygen need); laboratory data (C-reactive protein, white blood
cell count, urea, arterial blood gas analysis); and aetiology of pneumonia. Param-
eters with a p-value of <0.2 in univariate analysis were included in the forward
stepwise Cox proportional hazards model.
aCombination of malignancy, chronic obstructive pulmonary disease, congestive
heart failure, cerebrovascular disease, liver disease and kidney disease.
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